{"schema_version":"secwatch.filing_event.v1","accession":"0001703056-25-000021","form_type":"8-K","ticker":"ADT","cik":"0001703056","company_name":"ADT Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.500115+00:00","generated_at":"2026-05-26T02:14:39.479846+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ADT Q4 revenue +8%, FY GAAP EPS +40%, $500M buyback authorized","bullets":["Q4 revenue $1,260M (+8%), FY $4,898M (+5%); GAAP EPS $0.21 (Q4), $0.66 (FY), up 91%/40%.","Adjusted EPS $0.20 (Q4, +11%), $0.75 (FY, +25%); Adj FCF including swaps $744M (+42%).","Record customer retention: gross revenue attrition 12.7%; RMR $359M (+2%); 16 molecules in clinic.","Declared $0.055 dividend payable Apr 3; authorized $500M buyback through Apr 2026; redeemed $500M notes, new $600M term loan.","2025 guidance: revenue $5,025-$5,225M; Adj EBITDA $2,650-$2,750M; Adj EPS $0.77-$0.85; Adj FCF $800-$900M."],"urls":{"canonical":"https://secwatch.observer/filing/0001703056-25-000021","json":"https://secwatch.observer/filing/0001703056-25-000021.json","markdown":"https://secwatch.observer/filing/0001703056-25-000021.md","text":"https://secwatch.observer/filing/0001703056-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703056/000170305625000021/0001703056-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703056/000170305625000021/adt-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:14:39.479846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}